How much funding has Interface Biologics raised?

Interface Biologics has raised $8.0M in total funding, most recently a Series B round.

Who are Interface Biologics's investors?

Interface Biologics's investors include BDC Venture Capital, DSM Venturing, MaRS Investment Accelerator Fund, Covington Group.

When was Interface Biologics founded?

Interface Biologics was founded in 2001.

Where is Interface Biologics headquartered?

Interface Biologics is headquartered in Toronto, Canada.

What industry is Interface Biologics in?

Interface Biologics operates in Healthcare, Biotech.

Interface Biologics

Closed

Toronto, Canada · Founded 2001 · $8.0M raised

Healthcare

Biotech

Headquarters: Toronto
Founded: 2001
Business Model: B2B

Total Funding: $8.0M
Last Round: $1.0M Series BJan 2015
Rounds: 4

About

Interface Biologics is a Toronto-based biomaterials company, founded in 2001, that developed proprietary, nano-engineered surface-modification polymer technologies to improve the safety and performance of medical devices, including its Endexo platform used to reduce clot risk on implants. In 2019 the company sold its surface-modification business to Evonik, and its team went on to found the ophthalmic drug-delivery spinout Ripple Therapeutics in 2020.

Summary

Interface Biologics is a Healthcare company based in Toronto, Canada, founded in 2001. It has raised $8.0M in total across 4 rounds, most recently a $1.0M Series B round in Jan 2015. Investors include BDC Venture Capital, DSM Venturing and MaRS Investment Accelerator Fund.